When Molly Taylor started taking Mounjaro in the fall of 2024, she marveled at the speed of results. She wasn’t overweight, but she hadn’t been comfortable in her body. Now, she could eat whatever she ...

The number of GLP-1 users in the U.K. is now predicted to more than double, from three million to seven million by 2027. That’s not a trend. That’s a structural shift in how people eat. It means ...

Shipping and logistics companies are tapping into the growing healthcare market as cold chain and temperature-controlled facilities become more crucial. Those companies are investing millions of ...

Previous sleep research has focused mostly on the brain circuitry that snaps people awake in seconds or on how sleep debt ...

More than one in 10 Americans takes a GLP-1 medication for weight loss. As more people take a GLP-1, or glucagonlike peptide 1, receptor agonist, such as Wegovy, so, too, do more older adults—and ...

A new case report highlights the potential risk of "anhedonia" from high doses of tirzepatide, though it can be treated effectively. Reading time 3 minutes Weight isn’t the only thing people can lose ...

As use of GLP-1s surged across the U.S., average total payments per user also climbed sharply, according to a new Northwestern University study that analyzed national trends in GLP-1 use and spending ...

Please provide your email address to receive an email when new articles are posted on . GLP-1s can have a positive impact on bones and joints by reducing bone resorption and joint inflammation.

GLP-1 drugs could lead to cost savings for workers and their employers by reducing employee sick leave, a new economic study finds. Researchers found that patients who used the drugs, sold under brand ...

Pollsters recently asked a sample of adults in Britain who they would prefer to win the byelection in Clacton. The rather surprising answers showed that 33% favoured “comedy” candidate Count Binface, ...

This is read by an automated voice. Please report any issues or inconsistencies here. See more from the L.A. Times in Google Search. Set us as preferred Tom Holland is officially the first “Hot Ones” ...

Consumers will have to wait for broader insurance coverage of GLP-1 weight-loss drugs until prices come down and clear evidence emerges that they will reduce health care costs, the CEO of CVS Health, ...